178 related articles for article (PubMed ID: 18219443)
1. Burning mouth syndrome responsive to pramipexol.
Stuginski-Barbosa J; Rodrigues GG; Bigal ME; Speciali JG
J Headache Pain; 2008 Feb; 9(1):43-5. PubMed ID: 18219443
[TBL] [Abstract][Full Text] [Related]
2. In vivo mesolimbic D2/3 receptor binding predicts posttherapeutic clinical responses in restless legs syndrome: a positron emission tomography study.
Oboshi Y; Ouchi Y; Yagi S; Kono S; Nakai N; Yoshikawa E; Futatsubashi M; Terada T; Kim K; Harada K
J Cereb Blood Flow Metab; 2012 Apr; 32(4):654-62. PubMed ID: 22234337
[TBL] [Abstract][Full Text] [Related]
3. Burning mouth syndrome: Clinical description, pathophysiological approach, and a new therapeutic option.
Cárcamo Fonfría A; Gómez-Vicente L; Pedraza MI; Cuadrado-Pérez ML; Guerrero Peral AL; Porta-Etessam J
Neurologia; 2017 May; 32(4):219-223. PubMed ID: 26778734
[TBL] [Abstract][Full Text] [Related]
4. Pramipexole (Mirapex) for restless legs syndrome.
Med Lett Drugs Ther; 2007 Mar; 49(1257):26-8. PubMed ID: 17375031
[No Abstract] [Full Text] [Related]
5. Clinical experience with pramipexole in the treatment of restless legs syndrome.
Merlino G; Serafini A; Robiony F; Valente M; Gigli GL
Expert Opin Drug Metab Toxicol; 2008 Feb; 4(2):225-35. PubMed ID: 18248314
[TBL] [Abstract][Full Text] [Related]
6. Factors affecting the efficacy of pramipexole in patients with restless legs syndrome.
Rezvani M; Zamani B; Fereshtehnejad SM
Acta Med Iran; 2013 Jul; 51(6):377-85. PubMed ID: 23852842
[TBL] [Abstract][Full Text] [Related]
7. [Pramipexol: a new dopaminergic agonist for the treatment of Parkinson disease].
Grandas F; Galiano ML
Neurologia; 1999 May; 14(5):224-8. PubMed ID: 10377723
[TBL] [Abstract][Full Text] [Related]
8. Restless legs syndrome: differential diagnosis and management with pramipexole.
Brindani F; Vitetta F; Gemignani F
Clin Interv Aging; 2009; 4():305-13. PubMed ID: 19750232
[TBL] [Abstract][Full Text] [Related]
9. Burning mouth syndrome in Parkinson's disease: dopamine as cure or cause?
Coon EA; Laughlin RS
J Headache Pain; 2012 Apr; 13(3):255-7. PubMed ID: 22322657
[TBL] [Abstract][Full Text] [Related]
10. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome.
Trenkwalder C; Stiasny-Kolster K; Kupsch A; Oertel WH; Koester J; Reess J
Mov Disord; 2006 Sep; 21(9):1404-10. PubMed ID: 16755554
[TBL] [Abstract][Full Text] [Related]
11. The long-term effects of the dopamine agonist pramipexole in a proposed restless legs syndrome animal model.
Luo F; Li C; Ondo WG; Xu P; Xie W; Le W
Sleep Med; 2011 Jan; 12(1):41-6. PubMed ID: 21044864
[TBL] [Abstract][Full Text] [Related]
12. Preferential D2 or preferential D3 dopamine agonists in restless legs syndrome.
Manconi M; Ferri R; Zucconi M; Clemens S; Giarolli L; Bottasini V; Ferini-Strambi L
Neurology; 2011 Jul; 77(2):110-7. PubMed ID: 21715702
[TBL] [Abstract][Full Text] [Related]
13. A dose-ranging study of pramipexole for the symptomatic treatment of restless legs syndrome: polysomnographic evaluation of periodic leg movements and sleep disturbance.
Jama L; Hirvonen K; Partinen M; Alakuijala A; Hublin C; Tamminen I; Koester J; Reess J
Sleep Med; 2009 Jun; 10(6):630-6. PubMed ID: 19171500
[TBL] [Abstract][Full Text] [Related]
14. Reinforcing properties of Pramipexole in normal and parkinsonian rats.
Engeln M; Ahmed SH; Vouillac C; Tison F; Bezard E; Fernagut PO
Neurobiol Dis; 2013 Jan; 49():79-86. PubMed ID: 22940424
[TBL] [Abstract][Full Text] [Related]
15. Pramipexole in the treatment of restless legs syndrome: a follow-up study.
Montplaisir J; Denesle R; Petit D
Eur J Neurol; 2000 May; 7 Suppl 1():27-31. PubMed ID: 11054156
[TBL] [Abstract][Full Text] [Related]
16. Restless legs symptoms in a patient with above knee amputations: a case of phantom restless legs.
Hanna PA; Kumar S; Walters AS
Clin Neuropharmacol; 2004; 27(2):87-9. PubMed ID: 15252270
[TBL] [Abstract][Full Text] [Related]
17. Dopa responsive burning mouth syndrome: restless mouth syndrome or oral variant of restless legs syndrome?
Prakash S; Ahuja S; Rathod C
J Neurol Sci; 2012 Sep; 320(1-2):156-60. PubMed ID: 22819057
[TBL] [Abstract][Full Text] [Related]
18. Burning mouth syndrome.
Speciali JG; Stuginski-Barbosa J
Curr Pain Headache Rep; 2008 Aug; 12(4):279-84. PubMed ID: 18625105
[TBL] [Abstract][Full Text] [Related]
19. First night efficacy of pramipexole in restless legs syndrome and periodic leg movements.
Manconi M; Ferri R; Zucconi M; Oldani A; Fantini ML; Castronovo V; Ferini-Strambi L
Sleep Med; 2007 Aug; 8(5):491-7. PubMed ID: 17512780
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of pramipexole in restless legs syndrome.
Kruszewski SP; Shane J
Neurology; 2007 May; 68(19):1641; author reply 1641-2. PubMed ID: 17485661
[No Abstract] [Full Text] [Related]
[Next] [New Search]
